Synthesis and Pharmacological Characterization of Novel Druglike Corticotropin-Releasing Factor 1 Antagonists
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
To identify new CRF(1) receptor antagonists, an attempt to modify the bis-heterocycle moiety present in the top region of the dihydropyrrole[2,3]pyridine template was made following new pharmacophoric hypothesis on the CRF(1) receptor antagonists binding pocket. In particular, the 2-thiazole ring, present in the previous series of compounds, was replaced by more hydrophilic non aromatic heterocycles able to make appropriate H-bond interactions with amino acid residues Thr192 and Tyr195. This exploration, followed by an accurate analysis of the substitution of the pendant aryl ring, enabled to identify in vitro potent compounds showing excellent pharmacokinetics and outstanding in vivo activity in animal models of anxiety, both in rodents and primates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“using oral administration of the selective CRF-R1 antagonist GSK876008 (Di Fabio et al, 2008), at doses that dose dependently (linear) disrupt CRF-enhanced startle, we also observed a non-monotonic disruption of light-enhanced startle but no disruption of fear-potentiated startle in the same animals at the same doses”
From Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety (2010) · cites this paper as Di Fabio et al, 2008
Citations
Cites
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
VALE, W., SPIESS, J., RIVIER, C., & RIVIER, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
Holsboer, F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)90056-5 · Cited by 654
Rivier, C., & Vale, W. (1983) · Nature · doi:10.1038/305325a0 · Cited by 539
Habib, K. E., Weld, K. P., Rice, K. C., Pushkas, J., Champoux, M., Listwak, S., Webster, E. L., Atkinson, A. J., Schulkin, J., Contoreggi, C., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6079 · Cited by 403
De Souza, E. B. (1995) · Psychoneuroendocrinology · doi:10.1016/0306-4530(95)00011-9 · Cited by 395
Schulz, D. W., Mansbach, R. S., Sprouse, J., Braselton, J. P., Collins, J., Corman, M., Dunaiskis, A., Faraci, S., Schmidt, A. W., Seeger, T., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10477 · Cited by 377
Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist
Mansbach, R. S., Brooks, E. N., & Chen, Y. L. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)00025-3 · Cited by 195
Distress vocalization in rat pups a simple screening method for anxiolytic drugs
Gardner, C. R. (1985) · Journal of Pharmacological Methods · doi:10.1016/0160-5402(85)90031-2 · Cited by 181
Research works printed but not linked: 3
- Owen M. J., 1991, Pharmacol. Res., 43, 425
- Di Fabio R., 2008, J. Med. Chem.
- Arunlakshana O., 1959, Br. J. Pharmacol., 14, 48
Cited by
Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety
Davis, M., Walker, D. L., Miles, L., & Grillon, C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.109 · Cited by 1,513
“However, using oral administration of the selective CRF-R1 antagonist GSK876008 (Di Fabio et al, 2008), at doses that dose dependently (linear) disrupt CRFenhanced startle, we also observed a non-monotonic disruption of light-enhanced startle but no disruption of fear-potentiated startle in the…”
Walker, D. L., Miles, L. A., & Davis, M. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.06.022 · Cited by 331
“…potency (pA2) of 7.14 ± 0.12 on recombinant human CRF1 receptors expressed in CHO cells, but is inactive on human CRF2 receptors or the CRF binding protein, or on 83 other G-protein coupled receptors, channels, enzymes and transporters up to a concentration of 10 µM (di Fabio et al., 2008).”
BackgroundInfluentialProgress in corticotropin-releasing factor-1 antagonist development
Zorrilla, E. P., & Koob, G. F. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.02.011 · Cited by 167
“7), including the clinical candidate GW876008 (see below) [95].”
BackgroundZorrilla, E. P., Heilig, M., de Wit, H., & Shaham, Y. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.017 · Cited by 108
Kokras, N., Hodes, G. E., Bangasser, D. A., & Dalla, C. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14710 · Cited by 100
“Another CRF1 antagonist, verucerfont, lacked efficacy in a clinical trial of 150 depressed women, and no men (NCT00733980), despite the fact that the original behavioural testing was done in male animals (Fabio et al., 2008).”
BackgroundHubbard, C. S., Labus, J. S., Bueller, J., Stains, J., Suyenobu, B., Dukes, G. E., Kelleher, D. L., Tillisch, K., Naliboff, B. D., & Mayer, E. A. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-11.2011 · Cited by 98
Dunlop, B. W., Binder, E. B., Iosifescu, D., Mathew, S. J., Neylan, T. C., Pape, J. C., Carrillo-Roa, T., Green, C., Kinkead, B., Grigoriadis, D., et al. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.024 · Cited by 96
“GSK561679 is an orally active, selective CRF1 antagonist that demonstrates anxiolytic effects in animal models (33).”
Labus, J. S., Hubbard, C. S., Bueller, J., Ebrat, B., Tillisch, K., Chen, M., Stains, J., Dukes, G. E., Kelleher, D. L., Naliboff, B. D., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.016 · Cited by 90
“GW876008 (GlaxoSmithKline, Research Triangle Park, NC) is a highly selective and potent antagonist for the G-protein coupled CRF-R1 subtype.(22) Based on phase II clinical trials in patients with IBS, 20-mg and 200-mg doses of GW876008 were chosen in an attempt to provide a sufficient therapeutic range.”
Backgroundde Graaf, C., Rein, C., Piwnica, D., Giordanetto, F., & Rognan, D. (2011) · ChemMedChem · doi:10.1002/cmdc.201100317 · Cited by 72
Walker, D., Yang, Y., Ratti, E., Corsi, M., Trist, D., & Davis, M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.210 · Cited by 69
Self-citationBezençon, O., Heidmann, B., Siegrist, R., Stamm, S., Richard, S., Pozzi, D., Corminboeuf, O., Roch, C., Kessler, M. S., Ertel, E. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01236 · Cited by 66
Regioselective Synthesis, NMR, and Crystallographic Analysis of N1-Substituted Pyrazoles
Huang, A. J., Wo, K., Lee, S. Y. C., Kneitschel, N., Chang, J., Zhu, K., Mello, T., Bancroft, L., Norman, N. J., & Zheng, S. (2017) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.7b01006 · Cited by 64
Corticotropin releasing factor receptor antagonists for major depressive disorder
Paez-Pereda, M., Hausch, F., & Holsboer, F. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.565330 · Cited by 58
“gov Identifier: NCT00397722), but no results have been published so far [110].”
BackgroundThe CRH1 Antagonist GSK561679 Increases Human Fear But Not Anxiety as Assessed by Startle
Grillon, C., Hale, E., Lieberman, L., Davis, A., Pine, D. S., & Ernst, M. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.316 · Cited by 49
Aubry, J.-M. (2013) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2013.09.003 · Cited by 40
Anxiogenic effects of CGRP within the BNST may be mediated by CRF acting at BNST CRFR1 receptors
Sink, K. S., Chung, A., Ressler, K. J., Davis, M., & Walker, D. L. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.01.024 · Cited by 43
“The CRFR1 antagonist GSK876008 [24] was suspended at 5 mg/ml in 0.”
MethodSSRI or CRF antagonism partially ameliorate depressive-like behavior after adolescent social defeat
Bourke, C. H., Glasper, E. R., & Neigh, G. N. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.035 · Cited by 32
Ribecai, A., Bacchi, S., Delpogetto, M., Guelfi, S., Manzo, A. M., Perboni, A. D., Stabile, P., Westerduin, P., Hourdin, M., Rossi, S., et al. (2010) · Organic Process Research & Development · doi:10.1021/op100147h · Cited by 21
Self-citationStepannikova, K. O., Vashchenko, B. V., Grygorenko, O. O., Gorichko, M. V., Cherepakha, A., Moroz, Y. S., Volovenko, Y. M., & Zhersh, S. (2020) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202000351 · Cited by 21
Krasnokutskaya, E. A., Kassanova, A. Z., Estaeva, M. T., & Filimonov, V. D. (2014) · Tetrahedron Letters · doi:10.1016/j.tetlet.2014.05.052 · Cited by 18
Syntheses of 1-substituted-3-aminopyrazoles
Ji, N., Meredith, E. L., Liu, D., Adams, C. M., Artman, G. D., Jendza, K. C., Ma, F., Mainolfi, N., Powers, J. J., & Zhang, C. (2010) · Tetrahedron Letters · doi:10.1016/j.tetlet.2010.10.073 · Cited by 18
Methods for the synthesis of 1-substituted 1H-imidazol-2(3H)-ones
Antonova, M. M., Баранов, В. В., & Кравченко, А. Н. (2015) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-015-1716-3 · Cited by 17
Murrough, J. W., & Charney, D. S. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.012 · Cited by 17
Miller, D. C., Klute, W., Calabrese, A. A., & Brown, A. D. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.016 · Cited by 17
Provera, S., Rovatti, L., Turco, L., Mozzo, S., Spezzaferri, A., Bacchi, S., Ribecai, A., Guelfi, S., Mingardi, A., Marchioro, C., et al. (2010) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2010.06.012 · Cited by 14
“As part of a thorough exploration aimed at identiying of an innovative series of CRF1 receptor antagonists for the reatment of anxiety and depression, GW876008 (1) was recently eported as a potential lead compound in a wider series of dihyropyrrole[2,3]pyridine analogues [4].”
BackgroundSelf-citationChapter 6.1: Six-Membered Ring Systems: Pyridine and Benzo Derivatives
Hopper, D. W., Crombie, A. L., Clemens, J. J., & Kwon, S. (2009) · Progress in heterocyclic chemistry · doi:10.1016/s0959-6380(09)70039-x · Cited by 10
Synthesis of substituted terpyridine ligands for use in protein purification
Lin, C., Florio, P., Campi, E. M., Zhang, C., Fredericks, D. P., Saito, K., Jackson, W. R., & Hearn, M. T. W. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.09.074 · Cited by 9
Highly stereoselective synthesis of novel spiroimidazolidinones directed by pyridine prolinamide
Xiao, J., Wang, C., Wang, J., Ou, G., Zhang, X., & Yang, H. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.12.055 · Cited by 7
Ahuja, V. T., Hartz, R. A., Molski, T. F. P., Mattson, G. K., Lentz, K. A., Grace, J. E., Lodge, N. J., Bronson, J. J., & Macor, J. E. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.067 · Cited by 6
Pyridinyl trifluoromethanesulfonates: preparation methods and use in organic synthesis
Kassanova, A. Z., Krasnokutskaya, E. A., & Filimonov, V. D. (2016) · Russian Chemical Bulletin · doi:10.1007/s11172-016-1619-1 · Cited by 6
Novel one-pot synthesis of imidazolinones from esters: a concise synthesis of GSK2137305
Xing, N., Huang, J., Wang, P. G., Luo, L. E., Zheng, S., & He, L. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob02743b · Cited by 5
Copper‐Catalyzed CN Coupling on Large Scale: An Industrial Case Study
Ribecai, A., & Stabile, P. (2003) · doi:10.1002/9783527658909.ch10 · Cited by 5
Neuropeptide Receptors: Novel Therapeutic Targets for Depression and Anxiety Disorders
Chaki, S., & Kanuma, K. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00300 · Cited by 1
Ventral Tegmental Area Regulation Of Stress-Induced Reinstatement Of Cocaine-Seeking Behavior
Blacktop, J. M. (2014) · e-Publications@Marquette (Marquette University)
Metadata
- Authors
- Fabio, R. D., St-Denis, Y., Sabbatini, F. M., Andreotti, D., Arban, R., Bernasconi, G., Braggio, S., Blaney, F. E., Capelli, A. M., Castiglioni, E., Modugno, E. D., Donati, D., Fazzolari, E., Ratti, E., Feriani, A., Contini, S., Gentile, G., Ghirlanda, D., Provera, S., Marchioro, C., Roberts, K. L., Mingardi, A., Mattioli, M., Nalin, A., Pavone, F., Spada, S., Trist, D. G., & Worby, A.
- Affiliations
- GlaxoSmithKline (Italy) (IT)
- Neurosciences Centre of Excellence for Drug Discovery and Molecular Discovery Research, GlaxoSmithKline Medicines Research Centre, Via A. Fleming 4, 37135, Verona, Italy, Molecular Discovery Research, GlaxoSmithKline NFSP, Harlow, United Kingdom, GlaxoSmithKline Medicines Research Centre, Global Project Management, Via A. Fleming 4, 37135, Verona, Italy
- Corresponding author
- Fabio, Romano Di
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-11-07
- Volume
- 51
- Issue
- 23
- Pages
- 7370-7379
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1969850793
- Cited by
- 34
- References
- 19
- Citations by year
- 2020: 2 · 2019: 1 · 2017: 4 · 2016: 2 · 2015: 1 · 2014: 6 · 2013: 4 · 2012: 1
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Neurocrine Biosciences
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- CRF1 receptor antagonist, pharmacophore hypothesis, pharmacokinetics, anxiety models, nonhuman primate model
- MeSH terms
- CRF Receptor, Type 1, Animals, Dose-Response Relationship, Drug, Exploratory Behavior, Female, Forelimb, Gerbillinae, Humans, Male, Models, Chemical, Motor Activity, Psychological Tests, Pyridines, Pyrroles, Stereoisomerism, Ultrasonics, Vocalization, Animal, Molecular Structure, Rats, Sprague-Dawley, Receptors, Corticotropin-Releasing Hormone, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.